Literature DB >> 11487455

Cryptococcal Meningitis.

Lourdes Irizarry1.   

Abstract

Cryptococcal meningitis, often seen in immunocompromised hosts, is also a disease of the immune-competent individual. The diagnosis of cryptococcal meningitis requires a lumbar puncture with measurement of the opening pressure, standard laboratory assessment including cell count, protein and glucose, fungal culture, and cryptococcal polysaccharide antigen. Serum cryptococcal antigen is of great diagnostic value in individuals infected with HIV. Hospital admission for initial therapy with amphotericin B desoxycholate is required. Adjuvant oral therapy with flucytosine for the first 2 weeks of therapy is strongly recommended. If flucytosine is not well tolerated, it may be discontinued with close monitoring and follow-up of cerebrospinal fluid (CSF) response to therapy. Good hydration and appropriate premedication concomitant to the use of amphotericin B are useful interventions preventing side effects. Occasionally, amphotericin B needs to be discontinued due to intolerance or side effects. After CSF sterilization is completed, therapy can be switched to oral fluconazole. Fluconazole is well absorbed orally. There is rarely a need to give intravenous fluconazole.

Entities:  

Year:  2001        PMID: 11487455     DOI: 10.1007/s11940-001-0029-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  32 in total

1.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

2.  Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

Authors:  A C Leenders; P Reiss; P Portegies; K Clezy; W C Hop; J Hoy; J C Borleffs; T Allworth; R H Kauffmann; P Jones; F P Kroon; H A Verbrugh; S de Marie
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

3.  Latex-cryptococcal antigen test.

Authors:  L Kaufman; S Blumer
Journal:  Am J Clin Pathol       Date:  1973-08       Impact factor: 2.493

4.  Fluconazole and amphotericin B for cryptococcal meningitis.

Authors:  A B Clark; B L Lobo; M S Gelfand
Journal:  Ann Pharmacother       Date:  1996-12       Impact factor: 3.154

5.  Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis.

Authors:  E Mylonakis; N A Merriman; J D Rich; T P Flanigan; B C Walters; K T Tashima; M D Mileno; C M van der Horst
Journal:  Diagn Microbiol Infect Dis       Date:  1999-06       Impact factor: 2.803

6.  Pharmacokinetics of amphotericin B in children.

Authors:  J M Benson; M C Nahata
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  M S Saag; G A Cloud; J R Graybill; J D Sobel; C U Tuazon; P C Johnson; W J Fessel; B L Moskovitz; B Wiesinger; D Cosmatos; L Riser; C Thomas; R Hafner; W E Dismukes
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

9.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

10.  Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.

Authors:  J E Baley; C Meyers; R M Kliegman; M R Jacobs; J L Blumer
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.